Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellulitis | 9 | 2020 | 208 | 2.740 |
Why?
|
| Human papillomavirus 16 | 5 | 2014 | 266 | 0.700 |
Why?
|
| Skin | 6 | 2020 | 4464 | 0.590 |
Why?
|
| Lidocaine | 1 | 2018 | 537 | 0.500 |
Why?
|
| Langerhans Cells | 5 | 2015 | 170 | 0.490 |
Why?
|
| Neutrophils | 4 | 2021 | 3756 | 0.490 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 416 | 0.480 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 1406 | 0.420 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2019 | 803 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 6 | 2020 | 7399 | 0.380 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 218 | 0.350 |
Why?
|
| Virus Internalization | 2 | 2014 | 494 | 0.350 |
Why?
|
| Papillomavirus Infections | 6 | 2014 | 1602 | 0.340 |
Why?
|
| Receptors, Virus | 1 | 2013 | 639 | 0.330 |
Why?
|
| Home Care Services | 2 | 2020 | 647 | 0.220 |
Why?
|
| Annexin A2 | 2 | 2014 | 44 | 0.220 |
Why?
|
| Diagnostic Errors | 3 | 2019 | 1263 | 0.210 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2014 | 342 | 0.190 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 1994 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 15781 | 0.170 |
Why?
|
| Capsid Proteins | 3 | 2014 | 467 | 0.170 |
Why?
|
| Luminescence | 1 | 2020 | 108 | 0.170 |
Why?
|
| Papillomaviridae | 3 | 2015 | 1120 | 0.160 |
Why?
|
| Borrelia burgdorferi | 1 | 2021 | 183 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5798 | 0.160 |
Why?
|
| Dermatology | 2 | 2019 | 915 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3705 | 0.150 |
Why?
|
| Skin Temperature | 1 | 2017 | 96 | 0.140 |
Why?
|
| Remote Consultation | 1 | 2019 | 233 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 3608 | 0.130 |
Why?
|
| Leukocytosis | 1 | 2017 | 251 | 0.130 |
Why?
|
| Lyme Disease | 1 | 2021 | 630 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2017 | 777 | 0.120 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 243 | 0.120 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2015 | 74 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 433 | 0.120 |
Why?
|
| Tachycardia | 1 | 2017 | 600 | 0.120 |
Why?
|
| Foot Diseases | 1 | 2015 | 147 | 0.110 |
Why?
|
| Bronchiectasis | 1 | 2015 | 139 | 0.110 |
Why?
|
| Cost Savings | 1 | 2019 | 913 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2018 | 2929 | 0.110 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2013 | 112 | 0.100 |
Why?
|
| Virion | 1 | 2015 | 421 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 931 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 716 | 0.100 |
Why?
|
| S100 Proteins | 1 | 2012 | 218 | 0.100 |
Why?
|
| Leg | 1 | 2017 | 1088 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 616 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2015 | 580 | 0.090 |
Why?
|
| Physician's Role | 1 | 2018 | 916 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 4159 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 1458 | 0.090 |
Why?
|
| Emergencies | 1 | 2017 | 1209 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2018 | 1044 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 978 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1991 | 0.080 |
Why?
|
| Humans | 27 | 2021 | 757566 | 0.080 |
Why?
|
| Cell Survival | 1 | 2018 | 5781 | 0.080 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2009 | 99 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12951 | 0.080 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 177 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2012 | 979 | 0.070 |
Why?
|
| Immune Tolerance | 2 | 2014 | 2295 | 0.070 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 468 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2014 | 2901 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11057 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2018 | 3887 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2009 | 823 | 0.060 |
Why?
|
| Cytokines | 4 | 2015 | 7336 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3560 | 0.060 |
Why?
|
| Cell Line | 1 | 2018 | 15587 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15207 | 0.060 |
Why?
|
| Patient Preference | 2 | 2020 | 917 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2008 | 4641 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3415 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16881 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14637 | 0.050 |
Why?
|
| Complement C5 | 1 | 2021 | 106 | 0.050 |
Why?
|
| Risk Factors | 2 | 2019 | 73708 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 1046 | 0.040 |
Why?
|
| Age Factors | 1 | 2017 | 18326 | 0.040 |
Why?
|
| Emollients | 1 | 2019 | 41 | 0.040 |
Why?
|
| Male | 10 | 2019 | 358180 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7798 | 0.040 |
Why?
|
| Skin Diseases, Infectious | 1 | 2019 | 77 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2009 | 2720 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2020 | 341 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2019 | 500 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2017 | 42045 | 0.030 |
Why?
|
| Hospitals | 2 | 2020 | 3861 | 0.030 |
Why?
|
| Microfluidics | 1 | 2021 | 652 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 25924 | 0.030 |
Why?
|
| Female | 9 | 2019 | 389943 | 0.030 |
Why?
|
| Length of Stay | 2 | 2019 | 6384 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 550 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2019 | 1532 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 167718 | 0.030 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2015 | 288 | 0.030 |
Why?
|
| Cell Movement | 2 | 2019 | 5196 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 727 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2019 | 949 | 0.030 |
Why?
|
| HIV Infections | 1 | 2019 | 17270 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 167890 | 0.030 |
Why?
|
| Patient Admission | 1 | 2019 | 1364 | 0.020 |
Why?
|
| Middle Aged | 4 | 2019 | 219192 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 10167 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2012 | 428 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1201 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 1502 | 0.020 |
Why?
|
| Exanthema | 1 | 2015 | 505 | 0.020 |
Why?
|
| Swine | 1 | 2020 | 5891 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2009 | 107 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 219725 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 1788 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2014 | 1072 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1609 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6757 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1997 | 1840 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 39811 | 0.020 |
Why?
|
| Histones | 1 | 1997 | 2570 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3096 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 2685 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1997 | 2976 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 2502 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4110 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2015 | 3680 | 0.020 |
Why?
|
| Boston | 1 | 2017 | 9298 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3579 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2015 | 8296 | 0.010 |
Why?
|
| Quinolines | 1 | 2009 | 758 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2009 | 1036 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 3432 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2818 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 1557 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 7588 | 0.010 |
Why?
|
| Imidazoles | 1 | 2009 | 1178 | 0.010 |
Why?
|
| Logistic Models | 1 | 2017 | 13221 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 854 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2008 | 596 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 5786 | 0.010 |
Why?
|
| Peptides | 1 | 2014 | 4338 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 2203 | 0.010 |
Why?
|
| Papillomavirus Vaccines | 1 | 2008 | 489 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 64242 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2443 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 13442 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13463 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2012 | 3664 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 2859 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 17615 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12951 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 21986 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2008 | 1454 | 0.010 |
Why?
|
| Hemagglutinins | 1 | 1997 | 113 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 2006 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 9973 | 0.010 |
Why?
|
| RNA, Fungal | 1 | 1997 | 160 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41190 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 814 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 574 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 36045 | 0.010 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 1997 | 495 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 18936 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1997 | 1527 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 58755 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8503 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20499 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 1020 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 79984 | 0.010 |
Why?
|
| Child | 1 | 2017 | 79782 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 3734 | 0.000 |
Why?
|
| Mutation | 1 | 2012 | 29929 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13597 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 1997 | 5778 | 0.000 |
Why?
|
| Bacterial Proteins | 1 | 1997 | 3824 | 0.000 |
Why?
|
| Mice | 1 | 2008 | 81066 | 0.000 |
Why?
|
Concepts
(176)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(15)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_